CBF decreases after calcium antagonist treatment in acute ischemic stroke
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning
Standard
CBF decreases after calcium antagonist treatment in acute ischemic stroke. / Vorstrup, S; Paulson, O B; Andersen, A.
I: Agressologie, Bind 30, Nr. 7, 06.1989, s. 447-9.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - CBF decreases after calcium antagonist treatment in acute ischemic stroke
AU - Vorstrup, S
AU - Paulson, O B
AU - Andersen, A
PY - 1989/6
Y1 - 1989/6
N2 - The effect of the possible influence of a new calcium antagonist, PY 108-068, on regional cerebral blood flow (CBF) was studied in patients suffering acute ischemic stroke. The dosage was 1.5 + 2.5 mg intravenously in six patients (series 1) and 2.5 + 5.0 mg intravenously in five other patients (series 2). CBF was measured before and after treatment by xenon-133 inhalation and single photon emission computed tomography (Tomomatic 64). In the first series, no changes in hemispheric CBF, arterial blood pressure, or clinical symptoms were noted after treatment, but one patient showed an increase of CBF in part of the peri-infarct area. In the second series, slight increases in mean hemispheric flow values were seen, but in three of the five patients CBF decreased even further in the ischemic area. Arterial blood pressure decreased by 13%, and the clinical symptoms were unchanged. In conclusion the results shows, that calcium antagonist may be harmful in acute ischemic strokes since it can decrease the cerebral blood flow further in the ischemic areas. A potential beneficial metabolic effect of an calcium antagonist in ischemic tissue may thus be overshadowed by a harmful flow decrease.
AB - The effect of the possible influence of a new calcium antagonist, PY 108-068, on regional cerebral blood flow (CBF) was studied in patients suffering acute ischemic stroke. The dosage was 1.5 + 2.5 mg intravenously in six patients (series 1) and 2.5 + 5.0 mg intravenously in five other patients (series 2). CBF was measured before and after treatment by xenon-133 inhalation and single photon emission computed tomography (Tomomatic 64). In the first series, no changes in hemispheric CBF, arterial blood pressure, or clinical symptoms were noted after treatment, but one patient showed an increase of CBF in part of the peri-infarct area. In the second series, slight increases in mean hemispheric flow values were seen, but in three of the five patients CBF decreased even further in the ischemic area. Arterial blood pressure decreased by 13%, and the clinical symptoms were unchanged. In conclusion the results shows, that calcium antagonist may be harmful in acute ischemic strokes since it can decrease the cerebral blood flow further in the ischemic areas. A potential beneficial metabolic effect of an calcium antagonist in ischemic tissue may thus be overshadowed by a harmful flow decrease.
KW - Acute Disease
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Brain Ischemia/drug therapy
KW - Calcium Channel Blockers/therapeutic use
KW - Cerebrovascular Circulation/drug effects
KW - Female
KW - Humans
KW - Male
KW - Middle Aged
KW - Nifedipine/analogs & derivatives
M3 - Journal article
C2 - 2817242
VL - 30
SP - 447
EP - 449
JO - Agressologie
JF - Agressologie
SN - 0002-1148
IS - 7
ER -
ID: 275593237